Chargement des cours...
Prévisions
L'objectif de cours moyen des analystes est de 8,81 € (+1 298,41 %). La médiane est de 9,11 € (+1 346,03 %).
| Acheter |
18 |
| Conserver |
1 |
| Vendre |
0 |
Discussions dans la communauté
Il n'y a pas encore de discussion sur cet actif.
Lancer une discussionActualités Accéder au fil d'actualités
Aldeyra adds Darlene Deptula-Hicks to board of directors
Aldeyra has appointed Darlene Deptula-Hicks to its board of directors; she brings more than 30 years of experience in the biotech sector and expertise as a finance executive at public and private life-science companies. Deptula-Hicks is currently interim CFO of Normunity and was previously CFO of F-star Therapeutics; her experience with IPOs, capital raising and M&A is expected to support potential commercialization of Aldeyra’s therapies. Aldeyra is developing RASP modulators and is advancing reproxalap and ADX-2191 in late-stage development; the company has a market capitalization of $104 million, a current ratio of 2.72, and its stock has traded well below last year’s level since the start of the year, while analyst price targets remain between $2 and $13. » Plus sur de.investing.com
Aldeyra Therapeutics repays $15 million loan and terminates credit facility
Aldeyra Therapeutics repaid all outstanding liabilities of $15 million on April 1, thereby terminating the loan agreement with Hercules Capital in accordance with the contract. The company reports a balance sheet with more cash than debt and expects that cash, cash equivalents and marketable securities will fund operations through 2028. At the same time, Aldeyra faces regulatory pressure following an FDA Complete Response Letter for Reproxalap; analyst reactions are mixed (BTIG: buy, price target $9.00; H.C. Wainwright: neutral, price target $2.00). The stock trades well below last year’s level, reflecting the ongoing uncertainties. » Plus sur de.investing.com
Aldeyra Therapeutics: chief development officer Dr. Stephen G. Machatha to resign by March 2026
Aldeyra Therapeutics announced that Dr. Stephen G. Machatha has voluntarily resigned as chief development officer; his last day will be no later than March 31, 2026. The company and Machatha reached a transition agreement under which he will remain employed through his departure, continue to receive his base salary and benefits, and have outstanding equity awards remain unchanged. As part of the agreement, Machatha will receive a one‑time payment of $88,000 and may receive an additional $88,000 if he signs further release agreements after leaving. The company emphasized that the resignation is not the result of any disagreement with management or the board. » Plus sur de.investing.com
Aldeyra receives EMA orphan drug status for ADX-2191 to treat rare retinal diseases
Aldeyra Therapeutics has been granted orphan drug status by the European Medicines Agency for ADX-2191 for the treatment of inherited retinal dystrophies, including retinitis pigmentosa. The company will benefit from regulatory advantages and plans to conduct further clinical trials, while its financial position is described as solid. Additionally, progress has been reported in the development and approval applications of other medications. » Plus sur de.investing.com
Aldeyra receives positive FDA feedback for eye drug Reproxalap
Aldeyra Therapeutics has announced that the US Food and Drug Administration (FDA) has accepted the resubmitted approval application for its eye drug Reproxalap, intended for the treatment of dry eye disease. The FDA's decision is expected by December 16, 2025, following the submission of additional clinical data. Analysts remain optimistic about the stock, and the company is financially well positioned to continue its development programs. » Plus sur de.investing.com
Données financières de l'entreprise
| (EUR) | septembre 2026 | YoY |
|---|---|---|
| Chiffre d'affaires | 0 | - |
| Bénéfice brut | 0 | - |
| Bénéfice net | -3,32 M | 49,29 % |
| EBITDA | -3,19 M | 47,71 % |
Données fondamentales
| Indicateur | Valeur |
|---|---|
Capitalisation boursière | 38,23 M € |
Nombre d'actions | 60,36 M |
Plus haut/bas sur 52 semaines | 5,40 € - 0,48 € |
| Dividendes | Non |
Bêta | 1,29 |
Ratio P/E | -2,18 |
Ratio PEG | -0,02 |
Ratio P/B | 0,00 |
Ratio P/S | 0,00 |
Profil de l'entreprise
Aldeyra Therapeutics, Inc., une entreprise de biotechnologie, développe et commercialise des médicaments destinés aux maladies oculaires et systémiques à médiation immunitaire. Le produit candidat principal de la société est le reproxalap, un modulateur des espèces aldéhydiques réactives (RASP), qui est en essai clinique de phase III pour le traitement des maladies de l'œil sec et de la conjonctivite allergique. Elle développe également l'ADX-629, un modulateur RASP de première classe administrable par voie orale, qui est en essai clinique de phase II pour le psoriasis, l'asthme et la COVID-19 ; ainsi que l'ADX-2191, un inhibiteur de la dihydrofolate réductase, qui est en phase 3 pour la prévention de la vitréorétinopathie proliférative, et en essai clinique de phase II pour le traitement de la rétinite pigmentaire, ainsi que pour le traitement du lymphome vitréorétinien primitif. La société a conclu un accord de licence avec Madrigal Pharmaceuticals, Inc. pour le développement de l'ADX-1612, qui inhibe la protéine chaperome pour le traitement des maladies inflammatoires. La société était auparavant connue sous le nom d'Aldexa Therapeutics, Inc. et a changé de dénomination pour devenir Aldeyra Therapeutics, Inc. en mars 2014. Aldeyra Therapeutics, Inc. a été constituée en 2004 et son siège se trouve à Lexington, dans le Massachusetts.
| Nom | Aldeyra Therapeutics |
| PDG | Todd C. Brady |
| Siège social | Lexington,
ma États-Unis |
| Site web | |
| Secteur | Santé |
| Industrie | Biotechnologie |
| Introduction en bourse | 02/05/2014 |
| Employés | 6 |
Symboles boursiers
| Bourse | Symbole |
|---|---|
NASDAQ | ALDX |
Frankfurt | 137.F |
Düsseldorf | 137.DU |
München | 137.MU |